On Friday, U.S. stock index futures edged to a flat open for Wall Street, with major indexes on track for a fourth week of gains, following data on economic growth and to the lead of a report on consumer sentiment.

Insights about some real gainers from healthcare segment, in the recent trading session are depicted underneath:

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)’s shares skyrocketed 90.00% and is now trading at $2.07, as a development-stage biopharmaceutical company, formerly on February 18, 2015, the Board of Directors of Cyclacel Pharmaceuticals, Inc. declared a quarterly cash dividend in the amount of $0.15 per share on the Company’s 6% Convertible Exchangeable Preferred Stock. The cash dividend will be payable on May 1, 2015 to the holders of record of the Preferred Stock as of the close of business on April 17, 2015.

The Board considered numerous factors in determining whether to declare the quarterly dividend, counting the requisite financial analysis and determination of a surplus. While the Board will analyze the advisability of the declaration of dividends in future quarters, there is no assurance that future quarterly dividends will be declared.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine, Cyclacel’s most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has accomplished enrollment and is being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies for myelodysplastic syndromes (MDS) and chronic lymphocytic leukemia (CLL).

Shares of Second Sight Medical Products, Inc. (NASDAQ:EYES), jumped nearly 32.88% and is now trading at $15.68, as a medical device company, develops, manufactures, and markets implantable prosthetic devices, declared that all three of the centers approved to implant the Argus II Retinal Prosthesis System under the French Government national healthcare reimbursement program entitled ‘Forfait Innovation’ have successfully accomplished their first implants in patients with retinitis pigmentosa (RP). Current French implant centers are located in Paris, Bordeaux, and Strasbourg.

In 2014, the Argus II became the first-ever medical device to be named as the recipient of Forfait Innovation, allowing select hospitals in France to offer this “early access” and innovative treatment to patients with advanced RP. Forfait Innovation provides dedicated support to patients implanted with Argus II, funding the costs of implantation and patients’ hospital fees. 36 RP patients in France now stand to benefit from this life-changing technology with this first step in national reimbursement.

“We are happy to see RP patients, who formerly had no treatment option, gain access to this revolutionary device through Forfait Innovation,” stated Dr. Robert Greenberg, Chief Executive Officer of Second Sight. “There is great potential for patients in France, as the French government has taken a progressive step in supporting a sometimes overlooked patient population.”

RP, an inherited disease that often results in nearly complete blindness, affects roughly 24,000 French persons and 167,000 persons across Europe in total.

Second Sight Medical Products, Inc. (NASDAQ:EYES), also released that the company will release its 2014 fourth quarter and year-end financial results on Wednesday, March 11, 2015, after the close of the U.S. financial markets.

Second Sight Medical Products, Inc. was founded in 1998 to create a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations such as retinitis pigmentosa. Second Sight’s mission is to develop, manufacture, and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence.

Cytori Therapeutics, Inc. (NASDAQ:CYTX), surged 6.99% and is now trading at $1.21, soon after a cell therapy company, declared that it received approval from FDA to expand the number of Scleroderma clinical trial sites from 12 to 20 centers in the United States. The STAR study is an 80 patient pivotal clinical trial approved by FDA in January 2015 to study the effects of Cytori’s lead drug ECCS-50 for treatment of patients with hand manifestations of Scleroderma.

“Increasing the number of trial sites to 20 institutions should make the STAR trial more accessible to physicians and patients with scleroderma,” said Dr. Steven Kesten, Chief Medical Officer of Cytori Therapeutics. “There are only about 35 specialized scleroderma centers in the U.S. and this decision to expand the trial sites by FDA allows us to substantially broaden the geographic coverage of the trial, raise the number of centers trained in the use of this therapeutic and ultimately facilitate trial enrollment.”

Cytori Therapeutics, Inc. (NASDAQ:CYTX), is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair.

Shares of the Horizon Pharma plc (NASDAQ:HZNP), gained 8.91% & is now trading at $20.77, hitting new 52-week high of $21.45, after a specialty pharmaceutical company, focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, declared its fourth quarter and full year 2014 financial results today.

Fourth Quarter and Full Year 2014 Financial Results:

• Total net sales in the fourth quarter of 2014 were $103.8 million, contrast with $30.1 million in the fourth quarter of 2013, representing 245 percent year over year growth. Total net sales for the full year 2014 were $297.0 million, contrast with $74.0 million for the full year 2013, representing 301 percent year over year growth.

• Gross profit margins were 69 percent of net sales in the fourth quarter of 2014 contrast with 83 percent of net sales in the fourth quarter of 2013, and on a non-GAAP basis, were 94 percent of net sales in the fourth quarter of 2014 contrast with 93 percent of net sales in the fourth quarter of 2013, after not including depreciation, intangible amortization, amortization of inventory step-up and royalty re-measurement and accretion. Gross profit margins were 73 percent of net sales for the full year 2014 contrast with 80 percent of net sales for full year 2013, and on a non-GAAP basis, were 95 percent for full year 2014 contrast with 92 percent for full year 2013.

“We continued our strong momentum in the fourth quarter of 2014 and ended up surpassing our latest net sales and adjusted EBITDA guidance for the year,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. “We are also encouraged by the results we are seeing so far in 2015 and, as a result, we are raising 2015 full year guidance to $450 million to $475 million in net sales and $170 million to $190 million in adjusted EBITDA. Our projected strong operating cash flows and financial leverage support our ability to execute our strategy of continued product and company attainments to expand our commercial critical mass and further enhance shareholder value.”

Horizon Pharma plc (NASDAQ:HZNP), a specialty pharmaceutical company, through its auxiliaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. It offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA, and ankylosing spondylitis (AS).